IMMUNIC, INC. 8-K — AI Bull & Bear Analysis

The 8-K filing marks a fundamental pivot in Immunic's corporate identity, trading scientific leadership for commercial execution. While the hire of a seasoned industry veteran like Lundgren is a logical step for a company approaching a pivotal Phase 3 readout, the cost of this transition is high. Investors are now weighing the value of a proven commercial engine against a significantly more expensive executive layer and a governance structure that heavily protects the CEO regardless of clinical outcomes. The immediate impact is a shift in the investment thesis from purely scientific validation to commercial viability and capital management.